Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

encompass health corp. - EHC

EHC

Close Chg Chg %
98.90 0.47 0.48%

Open Market

99.37

+0.47 (0.48%)

Volume: 262.53K

Last Updated:

Nov 21, 2024, 1:48 PM EDT

Trade Now

Company Overview: encompass health corp. - EHC

EHC Key Data

Open

$98.76

 Day Range

98.09 - 99.65

52 Week Range

63.78 - 104.55

 Market Cap

$9.97B

Shares Outstanding

100.75M

 Public Float

99.20M

Beta

0.89

 Rev. Per Employee

N/A

P/E Ratio

23.88

 EPS

$4.21

Yield

62.67%

 Dividend

$0.17

EX-DIVIDEND DATE

Jan 2, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

766.08K

  

EHC Performance

1 Week
 
 0.08%
 
1 Month
 
 5.85%
 
3 Months
 
 8.14%
 
1 Year
 
 49.46%
 
5 Years
 
 73.80%
 

EHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About encompass health corp. - EHC

Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations. The Home Health and Hospice segment provides Medicare-certified home nursing, specialized home care and in-home services. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.

EHC At a Glance

Encompass Health Corp.
9001 Liberty Parkway
Birmingham, Alabama 35242
Phone 1-205-967-7116 Revenue 4.80B
Industry Medical/Nursing Services Net Income 349.60M
Sector Health Services 2023 Sales Growth 10.408%
Fiscal Year-end 12 / 2024 Employees 37,761
View SEC Filings

EHC Valuation

P/E Current 23.883
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 19.201
Price to Sales Ratio 1.408
Price to Book Ratio 4.06
Price to Cash Flow Ratio 7.944
Enterprise Value to EBITDA 10.142
Enterprise Value to Sales 2.124
Total Debt to Enterprise Value 0.288

EHC Efficiency

Revenue/Employee 127,147.056
Income Per Employee 9,258.229
Receivables Turnover 7.85
Total Asset Turnover 0.818

EHC Liquidity

Current Ratio 1.282
Quick Ratio 1.282
Cash Ratio 0.216

EHC Profitability

Gross Margin 19.443
Operating Margin 15.242
Pretax Margin 12.647
Net Margin 7.282
Return on Assets 6.161
Return on Equity 24.451
Return on Total Capital 7.895
Return on Invested Capital 8.234

EHC Capital Structure

Total Debt to Total Equity 178.015
Total Debt to Total Capital 64.031
Total Debt to Total Assets 48.06
Long-Term Debt to Equity 175.047
Long-Term Debt to Total Capital 62.963
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Encompass Health Corp. - EHC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
4.64B 5.12B 4.35B 4.80B
Sales Growth
+0.86% +10.27% -15.09% +10.41%
Cost of Goods Sold (COGS) incl D&A
3.84B 4.12B 3.56B 3.87B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
243.00M 256.60M 243.60M 273.90M
Depreciation
183.20M 200.20M 214.80M 241.40M
Amortization of Intangibles
59.80M 56.40M 28.80M 32.50M
COGS Growth
+4.79% +7.20% -13.45% +8.52%
Gross Income
803.30M 1.00B 784.50M 933.50M
Gross Income Growth
-14.50% +24.96% -21.85% +18.99%
Gross Profit Margin
+17.30% +19.60% +18.04% +19.44%
2020 2021 2022 2023 5-year trend
SG&A Expense
155.50M 197.30M 154.30M 201.70M
Research & Development
- - - -
-
Other SG&A
155.50M 197.30M 154.30M 201.70M
SGA Growth
-37.04% +26.88% -21.79% +30.72%
Other Operating Expense
- - - -
-
Unusual Expense
- 4.70M (2.80M) 8.80M
EBIT after Unusual Expense
643.10M 809.30M 621.40M 731.80M
Non Operating Income/Expense
13.70M 12.50M 5.10M 18.90M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
3.50M 4.00M 2.90M 3.20M
Interest Expense
184.20M 164.60M 175.70M 143.50M
Interest Expense Growth
+15.34% -10.64% +6.74% -18.33%
Gross Interest Expense
190.20M 173.50M 186.20M 157.00M
Interest Capitalized
6.00M 8.90M 10.50M 13.50M
Pretax Income
472.60M 657.20M 450.80M 607.20M
Pretax Income Growth
-15.95% +39.06% -31.41% +34.69%
Pretax Margin
+10.18% +12.83% +10.37% +12.65%
Income Tax
103.80M 139.60M 100.10M 132.20M
Income Tax - Current - Domestic
51.40M 111.80M 72.20M 128.30M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
52.40M 27.80M 27.90M 3.90M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
3.50M 4.00M 2.90M 3.20M
Other After Tax Income (Expense)
(1.00M) (1.80M) (1.10M) (2.40M)
Consolidated Net Income
367.80M 515.80M 349.60M 472.60M
Minority Interest Expense
84.60M 105.00M 93.60M 111.00M
Net Income
283.20M 410.80M 256.00M 361.60M
Net Income Growth
-20.89% +45.06% -37.68% +41.25%
Net Margin Growth
+6.10% +8.02% +5.89% +7.53%
Extraordinaries & Discontinued Operations
- (400.00K) 13.80M (12.00M)
Discontinued Operations
- (400.00K) 13.80M (12.00M)
Net Income After Extraordinaries
283.20M 410.40M 269.80M 349.60M
Preferred Dividends
- - - -
-
Net Income Available to Common
283.20M 410.40M 269.80M 349.60M
EPS (Basic)
2.8722 4.1454 2.7198 3.5136
EPS (Basic) Growth
-21.24% +44.33% -34.39% +29.19%
Basic Shares Outstanding
98.60M 99.00M 99.20M 99.50M
EPS (Diluted)
2.8477 4.1138 2.6992 3.4748
EPS (Diluted) Growth
-21.09% +44.46% -34.39% +28.73%
Diluted Shares Outstanding
99.80M 100.20M 100.40M 101.30M
EBITDA
890.80M 1.06B 873.80M 1.01B
EBITDA Growth
-2.24% +19.34% -17.81% +15.09%
EBITDA Margin
+19.18% +20.76% +20.09% +20.95%

Snapshot

Average Recommendation BUY Average Target Price 113.583
Number of Ratings 14 Current Quarters Estimate 1.028
FY Report Date 12 / 2024 Current Year's Estimate 4.291
Last Quarter’s Earnings 1.03 Median PE on CY Estimate N/A
Year Ago Earnings 3.64 Next Fiscal Year Estimate 4.775
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 11 13 13
Mean Estimate 1.03 1.19 4.29 4.78
High Estimates 1.13 1.34 4.45 5.25
Low Estimate 0.98 1.06 4.13 4.45
Coefficient of Variance 4.38 5.96 1.74 4.93

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 11
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Encompass Health Corp. - EHC

Date Name Shares Transaction Value
Oct 18, 2024 Nancy M. Schlichting Director 19,659 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 18, 2024 Christopher R. Reidy Director 11,879 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 18, 2024 Christopher R. Reidy Director 12,241 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $97.53 per share 1,193,864.73
Oct 18, 2024 Terrance Williams Director 13,622 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Gregory D. Carmichael Director 17,074 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Kevin J. O'Connor Director 8,401 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Joan Elizabeth Herman Director 45,941 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Patricia A. Maryland Director 13,244 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Edward Morgan Christie Director 4,122 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $86.8 per share 357,789.60
Jul 18, 2024 Edward Morgan Christie Director 3,788 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2024 Leslye G. Katz Director 45,941 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2024 John Patrick Darby EVP, Gen Counsel & Secretary 84,773 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.94 per share 7,115,845.62
May 7, 2024 John Patrick Darby EVP, Gen Counsel & Secretary 99,316 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $29.06 per share 2,886,122.96
May 7, 2024 John Patrick Darby EVP, Gen Counsel & Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 2, 2024 Mark J. Tarr President & CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 2, 2024 Mark J. Tarr President & CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 2, 2024 Mark J. Tarr President & CEO; Director 554,098 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.27 per share 46,139,740.46
May 2, 2024 Mark J. Tarr President & CEO; Director 599,074 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $29.06 per share 17,409,090.44
May 2, 2024 Mark J. Tarr President & CEO; Director 573,558 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $35.83 per share 20,550,583.14
Apr 17, 2024 John W. Chidsey Director 162,826 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $79.52 per share 12,947,923.52

Encompass Health Corp. in the News